Financial Data and Key Metrics Changes - The company reported an 11% headline revenue growth and a 9% growth on a constant currency basis for the second quarter of fiscal year 2026, with GAAP EPS growth of 16% [4][28] - Gross margin increased by 110 basis points year-over-year and by 30 basis points sequentially, reaching 62%-63% for fiscal year 2026 [30][31] - Operating profits increased by 19%, with an operating margin improvement to 36.3% compared to 34% in the prior year [32] Business Line Data and Key Metrics Changes - Global devices revenue experienced high single-digit growth, while masks, accessories, and other revenue saw double-digit growth [4][5] - Residential care software revenue increased by 5% on a constant currency basis, driven by strong performance from the Medifox Dan software vertical [30] Market Data and Key Metrics Changes - Sales in the U.S., Canada, and Latin America increased by 11%, with a 6% increase on a constant currency basis [29] - In Europe, Asia, and other regions, device sales increased by 5% on a constant currency basis, while masks and other sales increased by 8% [29] Company Strategy and Development Direction - The company aims to build a leading digital health ecosystem encompassing sleep health, breathing health, and healthcare technology delivered in the home [8] - Continued focus on operational excellence and innovation, with a commitment to R&D investments of 6%-7% of revenues and SG&A investments of 19%-20% [26][31] - The company is expanding its digital sleep health concierge capabilities and enhancing its manufacturing footprint to improve delivery efficiency [10][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in re-accelerating growth in Europe, Asia, and the rest of the world, with expectations of sustainable high single-digit growth in the residential care software business by fiscal year 2027 [5][6] - The company is closely monitoring the global trade environment and regulatory landscape, with positive implications from recent developments in competitive bidding programs [21][23] Other Important Information - The company returned $263 million to shareholders through dividends and $175 million in share repurchases during the quarter, with plans to increase share repurchases to over $600 million for fiscal year 2026 [34][26] - The launch of new AI-enabled products, such as Comfort Match, is expected to enhance patient adherence to therapy [12][19] Q&A Session Summary Question: Strong US mask number and impact of Virtuox - Management confirmed that the strong growth in masks includes contributions from Virtuox, but even without it, there was solid double-digit growth in masks and accessories [36][38] Question: Update on GLP-1 landscape and its impact - Management noted a 10%-11% higher start rate for CPAP therapy among patients with GLP-1 prescriptions, indicating a motivated patient group [39][41] Question: SG&A growth ahead of revenue growth - Management explained that the SG&A growth includes impacts from the Virtuox acquisition and promotional activities, but underlying growth is tracking closely with revenue [43] Question: Impact on patient funnel stages - Management highlighted significant progress in the top of the funnel due to increased awareness from Big Pharma and tech, while focusing on scaling home sleep apnea testing [45][47] Question: Potential return of Philips to the US market - Management expressed confidence in competing effectively against Philips, noting that they have been performing well in various markets despite Philips' presence [60][62]

Group 1 - The company, Brainstorm Aurora-B (06681), has entered into a placement and subscription agreement, with a share placement price set at HKD 5.6 per share, representing a discount of approximately 12.09% from the last closing price of HKD 6.37 [1] - The placement shares will account for about 7.27% of the company's existing issued share capital as of the announcement date, and approximately 6.77% after the completion of the subscription [1] Group 2 - The total estimated proceeds from the subscription are approximately HKD 515 million, with a net amount expected to be around HKD 501 million after deducting all related costs and expenses [2] - The company plans to allocate approximately 50% of the net proceeds for research and development programs, including the development of non-invasive brain-computer interface systems and consumer-oriented digital health platforms, expected to be fully utilized by September 30, 2027 [2] - About 30% of the net proceeds will be used for domestic and international market development, including costs related to establishing national branches and supporting academic conferences, expected to be fully utilized by June 30, 2027 [2] - Approximately 10% of the net proceeds will be allocated for strategic investments and acquisitions within the digital health ecosystem, expected to be fully utilized by June 30, 2027 [2] - The remaining 10% will be used to supplement the company's general working capital, expected to be fully utilized by December 31, 2026 [2]

Core Insights - The board of Ark Health (06086.HK) noted a recent increase in the company's share price on September 12, 2025 [1] - The company announced its proprietary "Xing Shi" large model as a cornerstone for five flagship applications aimed at enhancing clinical diagnostic support and personalized chronic disease management [1] - Strategic partnerships were established with Innovent Biologics and Otsuka Pharmaceutical to integrate digital health solutions and improve patient outcomes in the growing weight management market in China [1] Summary by Categories - **Share Price Movement** - The board observed a rise in the company's share price on September 12, 2025 [1] - **Product Development** - The company launched the "Xing Shi" large model, which serves as the foundation for five key applications: AI Drug Assistant, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI Search [1] - **Strategic Partnerships** - A partnership with Innovent Biologics was formed to integrate Ark's digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model for personalized digital support [1] - Collaboration with Otsuka Pharmaceutical aims to combine AI technology with Otsuka's innovative drug portfolio to develop comprehensive digital solutions for drug support services and health education programs [1]